Author: Miyakawa, K.; Jeremiah, S. S.; Kato, H.; Ryo, A.
Title: Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant Cord-id: 4fyuruiw Document date: 2021_9_26
ID: 4fyuruiw
Snippet: The rise of mutant strains of SARS-CoV-2 poses an additional problem to the existing pandemic of COVID-19. There are rising concerns about the Mu variant which can escape humoral immunity acquired from infections from previous strains or vaccines. We examined the neutralizing efficacy of the BNT162b2 mRNA vaccine against the Mu variant and report that the vaccine has 76% neutralizing effectiveness against the Mu compared to 96% with the original strain. We also show that Mu, similar to the Delta
Document: The rise of mutant strains of SARS-CoV-2 poses an additional problem to the existing pandemic of COVID-19. There are rising concerns about the Mu variant which can escape humoral immunity acquired from infections from previous strains or vaccines. We examined the neutralizing efficacy of the BNT162b2 mRNA vaccine against the Mu variant and report that the vaccine has 76% neutralizing effectiveness against the Mu compared to 96% with the original strain. We also show that Mu, similar to the Delta variant, causes cell-to-cell fusion which can be an additional factor for the variant to escape vaccine-mediated humoral immunity. Despite the rise in vaccine escape strains, the vaccine still possesses adequate ability to neutralize majority of the mutants.
Search related documents:
Co phrase search for related documents- luciferase activity and luminescence signal: 1
- luciferase signal and luminescence signal: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date